 At that point, because the data was so robust and showed so clearly how safe mifepristone is, the FDA changed the reporting requirements. Even so, the FDA still required more reporting for mifepristone than for almost any other drug. But it was bringing it closer to the type of reporting that FDA uses across the board for all other medications. What are you saying, Catherine, is getting wrong there?